November 12, 2008
Favorable Endologix Powerlink XL System Clinical Data to Be Announced November 20 at Veith Symposium
Endologix, Inc. (NASDAQ:ELGX), the developer and manufacturer of the Powerlink(R) System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that the one-year results from its Powerlink XL(R) prospective, multi-center clinical trial will be presented on November 20, 2008 at the 35th Annual VEITH Symposium(TM) being held in New York City. Data from this clinical study were obtained under a U.S. Food and Drug Administration-approved Investigational Device Exemption (IDE) and were submitted to the Agency earlier this year.
As a study principal investigator, Professor William D. Jordan, Jr., M.D. (Chief of Vascular Surgery, UAB Hospital, Birmingham, Alabama) will be discussing the study results in his presentation entitled, "Inhibition of Migration Following EVAR in Patients with Wide Aortic Necks: A Multicenter Prospective Trial." Endologix plans to announce these clinical data in a press release to be issued immediately following Dr. Jordan's presentation.Additional presentations at the VEITH Symposium featuring the Powerlink System are as follows:
-- "Use of Extension Cuffs and Placing the Body of the Powerlink Graft on the Bifurcation is the Best Way to Treat Most Difficult Aortic Necks," presented by Professor Dieter Raithel, M.D., Ph.D. (Southern Clinic, Nuremburg, Germany) on Saturday, November 22.
-- "There is No Difference in Post-EVAR Morbidity and Mortality Depending on AAA Size: Big is Not Really Worse," presented by Jeffrey P. Carpenter, M.D. (Chief of Surgery, Cooper University Hospital, NJ), on Sunday, November 23.
"We are delighted to announce data from our Powerlink XL clinical trial at the prestigious VEITH Symposium. This venue provides an ideal opportunity to increase awareness for this new product that offers the lowest profile catheter of all commercially available devices in the U.S. indicated for aortic necks greater than 26 millimeters," said John McDermott, Endologix President and CEO.
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.